Article Top Ad
Reading Time: 3 minutes

Vancouver, British Columbia–(Newsfile Corp. – November 17, 2021) –  Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, has been selected to join a three year research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All. The US$975,000, or CDN$1,297,000, research program is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

For more information, please view the InvestmentPitch Media “video” which provides additional information about this news and the company. If this link is not enabled, please visit and enter “Rakovina” in the search box.

Cannot view this video? Visit:

Martha’s Better Ewing Sarcoma Treatment (BEST) Grant for All is a St. Baldrick’s grant named in honor of a 19-year-old girl who has fought the disease for over 6 years, after first being diagnosed with Ewing sarcoma in 2015, at the age of 13. Martha was happy to have her name associated with the grant but insisted on the “for All” to recognize the many other children diagnosed with Ewing sarcoma every year. Having faced numerous relapses over the years, Martha is undeterred and continues her battle against Ewing Sarcoma. Continuing to put her faith behind the cancer research community, Martha plans to enroll in a clinical trial at Boston Children’s Hospital in December 2021.

Prof. Mads Daugaard, Rakovina Therapeutics president and chief scientific officer, is a principal researcher in the project along with Prof. Poul Sorensen at the University of British Columbia. Rakovina Therapeutics recently presented preclinical data at peer reviewed scientific meetings demonstrating the potential of Rakovina Therapeutics’ kt-3000 series drug candidates against treatment-resistant cancer cell lines, including Ewing sarcoma.

Prof. Mads Daugaard, Rakovina’s President and Chief Scientific Officer, stated: “Our data demonstrate that kt-3000 series compounds are equal or more effective against Ewing sarcoma cells in vitro in comparison to FDA approved PARP-inhibitors, which are used as benchmarks for activity. Currently, there are no FDA-approved treatments for relapsed Ewing sarcoma, which is largely resistant to conventional therapies as well as immunotherapy; new treatment strategies are sorely needed.

Kathleen Ruddy, CEO, St. Baldrick’s Foundation, added: “This incredibly generous major gift made it possible for us to partner with the University of British Columbia to seek out and fund new Ewing sarcoma research. Recently reported data from Rakovina Therapeutics demonstrate early promise as a potential treatment for Ewing sarcoma and we are pleased to welcome the company into this important project, which supports cutting-edge research in the hopes of finding new treatments for this deadly disease. Thousands of donors and volunteers have made the St. Baldrick’s Foundation the largest non-government funder of childhood cancer research grants. Our volunteers and scientists work tirelessly to ensure that current and future children diagnosed with cancer will have access to the best treatments and that tomorrow’s cures will come with fewer long-term toxic effects.”

Jeffrey Bacha, Rakovina’s Executive Chairman, commented: “Rakovina Therapeutics is pleased to be an industry partner in the St. Baldrick’s Foundation mission to support the most promising research to find cures for childhood cancers and give survivors long and healthy lives. We will seek to rapidly advance drug candidates into the clinical arena if pre-clinical IND-enabling work permits.

Rakovina Therapeutics was established in 2020 to develop new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies.

The shares, which began trading on April 1st, are currently trading at $0.23. For more information, please visit the company’s website, contact David Hyman, CFO, at 403-613-1453 or by email at [email protected]. For investor relations email [email protected].

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

InvestmentPitch Media
Barry Morgan, CFO
[email protected]

To view the source version of this press release, please visit

Powered by WPeMatico